By analogy for the sole purpose of this guidance, a manufacturing site located in a third country engaged in the manufacture of medicinal products (produced using WFI) which are exported to the European Union and where a Mutual Recognition Agreement, or equivalent agreement exists between the country concerned and the European Union and the affected products are within the operational scope of the agreement, it is the relevant competent authority responsible for GMP oversight in the country concerned.